Loading
A phase 2/3 trial of Etoposide in small-cell lung cancer, run by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, active and no longer recruiting.
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT01064466 by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, with 600 participants enrolled, started 2025-07-16 and due to reach its primary completion in 2026-11-18. Interventions recorded: ETOPOSIDE - Usual and ETOPOSIDE - Study.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Shares Etoposide, Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/